-
Mashup Score: 6Encorafenib, cetuximab and chemotherapy in BRAF-mutant colorectal cancer: a randomized phase 3 trial - 5 hour(s) ago
Nature Medicine – As presented at the 2025 ASCO GI Cancers Symposium: in the phase 3 BREAKWATER trial, patients with previously untreated BRAF V600E metastatic colorectal cancer received the BRAF…
Source: www.nature.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 18Encorafenib, cetuximab and chemotherapy in BRAF-mutant colorectal cancer: a randomized phase 3 trial - 9 hour(s) ago
Nature Medicine – As presented at the 2025 ASCO GI Cancers Symposium: in the phase 3 BREAKWATER trial, patients with previously untreated BRAF V600E metastatic colorectal cancer received the BRAF…
Source: www.nature.comCategories: General Medicine News, Hem/OncsTweet-
RT @ArndtVogel: Encorafenib, cetuximab and chemotherapy in BRAF-mutant colorectal cancer: https://t.co/ujDekXSi1d @NatureMedicine 🔎BREAKWA…
-
-
Mashup Score: 2Pembrolizumab and chemotherapy in high-risk, early-stage, ER+/HER2− breast cancer: a randomized phase 3 trial - 9 day(s) ago
Nature Medicine – In this prespecified interim analysis of the KEYNOTE-756 phase 3 trial, pembrolizumab and chemotherapy treatment of patients with high-risk, early-stage, estrogen…
Source: www.nature.comCategories: General Medicine News, Hem/OncsTweet-
RT @tuttsakhil: https://t.co/xpqR1rWQix
-
-
Mashup Score: 11Cancer Trial Results - 25 day(s) ago
Clin Larvol | Cancer Trial Results
Source: clin.larvol.comCategories: General Medicine News, Hem/OncsTweet-
@mtmdphd @grpetersen1 @bdermanmd @HadidiSamer @jmikhaelmd @MyelomaTeacher @RahulBanerjeeMD @rajshekharucms @szusmani @End_myeloma @bhemato @MeeraMohanMD @myelomaMD @VincentRK @CyclingDoctor @Amyloid_Planet @MayoMyeloma OncoBuzz so far (https://t.co/F0b1m8s1Hw) https://t.co/zrlfbQEwQT
-
-
Mashup Score: 1
Nature Reviews Clinical Oncology – Ipilimumab plus nivolumab efficacious in patients with dMMR/MSI-H disease
Source: www.nature.comCategories: General Medicine News, Hem/OncsTweet-
RT @SyedAAhmad5: Ipilimumab plus nivolumab efficacious in patients with dMMR/MSI-H disease @NatRevClinOncol https://t.co/VxcZrG6ygT
-
-
Mashup Score: 2Careers - KeyCDN - 1 month(s) ago
KeyCDN is made up of an international team that has built a high performance content delivery network. Join our team today.
Source: www.keycdn.comCategories: General Medicine News, Hem/OncsTweet-
RT @KerjaRemote_: KeyCDN - https://t.co/TQfwY5RSfR Kinsta - https://t.co/ptUZCKhaSn Kumu - https://t.co/Rc182mESHD Larvol - https://t.co/hh…
-
-
Mashup Score: 11Cancer Trial Results - 1 month(s) ago
Clin Larvol | Cancer Trial Results
Source: clin.larvol.comCategories: General Medicine News, Hem/OncsTweet-
@mtmdphd @grpetersen1 @bdermanmd @HadidiSamer @jmikhaelmd @MyelomaTeacher @RahulBanerjeeMD @rajshekharucms @szusmani @End_myeloma @bhemato @MeeraMohanMD @myelomaMD @VincentRK @CyclingDoctor @Amyloid_Planet @MayoMyeloma OncoBuzz so far (https://t.co/F0b1m8s1Hw) https://t.co/zrlfbQEwQT
-
-
Mashup Score: 0AQUILA - A Study of Subcutaneous Daratumumab Versus Active Monitoring in Participants With High-Risk Smoldering Multiple Myeloma - 1 month(s) ago
Check this out – AQUILA – A Study of Subcutaneous Daratumumab Versus Active Monitoring in Participants With High-Risk Smoldering Multiple Myeloma
Source: clin.larvol.comCategories: General Medicine News, Hem/OncsTweet-
@majorajay @NEJM Our current CLIN rating is “positive” (not practice informing or changing). @sweta_agrw https://t.co/DuzyzEDw7F https://t.co/7GkriBCwm0
-
-
Mashup Score: 41
Nature Reviews Clinical Oncology – Third-generation EGFR tyrosine-kinase inhibitors (TKIs) are the standard-of-care first-line treatment for patients with advanced-stage EGFR-mutant NSCLC and their…
Source: www.nature.comCategories: General Medicine News, Hem/OncsTweet-
RT @dr_yakupergun: The changing treatment landscape of EGFR-mutant non-small-cell lung cancer 💥Excellent review👇 https://t.co/0uCdT73TxD…
-
-
Mashup Score: 41
Nature Reviews Clinical Oncology – Third-generation EGFR tyrosine-kinase inhibitors (TKIs) are the standard-of-care first-line treatment for patients with advanced-stage EGFR-mutant NSCLC and their…
Source: www.nature.comCategories: General Medicine News, Hem/OncsTweet-
RT @dr_yakupergun: The changing treatment landscape of EGFR-mutant non-small-cell lung cancer 💥Excellent review👇 https://t.co/0uCdT73TxD…
-
RT @ArndtVogel: Encorafenib, cetuximab and chemotherapy in BRAF-mutant colorectal cancer: https://t.co/ujDekXSi1d @NatureMedicine 🔎BREAKWA…